GLOW (GHK-Cu + BPC-157 +…Vial · 70 mg
Mon–Fri 9:00–19:00, Sat 10:00–15:00
Vial · 50 mg
A triple agonist of the GIP, GLP-1 and glucagon receptors. In clinical development.
Retatrutide is a synthetic peptide by Eli Lilly that activates three receptors at once: GIP, GLP-1 and glucagon.
In 2026 four phase III TRIUMPH trials in obesity were completed. In the main one (TRIUMPH-1), participants on the highest dose lost on average about 28% of body weight over 80 weeks. Eli Lilly plans to submit it to the FDA in the first quarter of 2027.
| Component | Amount |
|---|---|
| Retatrutide | 50 mg / vial |
Lyophilized powder for preparing a solution. Sold for scientific and laboratory research.
Documents for this batch will appear here soon.
All store certificates →